These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 34930261)

  • 1. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
    Cai W; Bao W; Chen S; Yang Y; Li Y
    Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
    Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
    J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
    Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
    Front Oncol; 2021; 11():674897. PubMed ID: 34367961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
    Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
    Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Transcriptomic Signatures of Pancreatic Ductal Adenocarcinoma-Derived Exosomes That Promote Macrophage M2 Polarization and Predict Prognosis: S100A9 Reveals Tumor Progression.
    Tan S; Tang H; Zhang Z; Wang Y; Li H; Shi W; Ye H; Xie P; Zhou J
    Clin Med Insights Oncol; 2024; 18():11795549241239042. PubMed ID: 38510315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
    Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of solute carrier family genes related to the prognosis and tumor-infiltrating immune cells of pancreatic ductal adenocarcinoma.
    Meng Y; Li Y; Fang D; Huang Y
    Ann Transl Med; 2022 Jan; 10(2):57. PubMed ID: 35282128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients.
    Zhang D; Wang M; Peng L; Yang X; Li K; Yin H; Xia C; Cui F; Huang H; Jin Z
    J Oncol; 2021; 2021():4986227. PubMed ID: 34987579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study.
    Yang F; He Y; Ge N; Guo J; Yang F; Sun S
    Front Immunol; 2023; 14():1203459. PubMed ID: 38268915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
    Ren M; Feng L; Zong R; Sun H
    World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
    Xu X; Liang JH; Xu QC; Yin XY
    Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
    Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
    Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a prognostic model with exosome biogenesis- and release-related genes and identification of RAB27B in immune infiltration of pancreatic cancer.
    Li TY; Qin C; Zhao BB; Li ZR; Wang YY; Zhao YT; Wang WB
    Transl Cancer Res; 2024 Sep; 13(9):4846-4865. PubMed ID: 39430819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.
    Lu H; Zheng LY; Wu LY; Chen J; Xu N; Mi SC
    Front Oncol; 2022; 12():978921. PubMed ID: 36147906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
    Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
    Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma.
    Fang L; Chen S; Gong H; Xia S; Guan S; Quan N; Li Y; Zeng C; Chen Y; Du J; Liu S
    Front Oncol; 2022; 12():1060508. PubMed ID: 36727081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.
    Huang X; Zhao L; Jin Y; Wang Z; Li T; Xu H; Wang Q; Wang L
    Front Oncol; 2022; 12():827051. PubMed ID: 35433491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDX21 functions as a potential novel oncopromoter in pancreatic ductal adenocarcinoma: a comprehensive analysis of the DExD box family.
    Wu S; Sun X; Hua R; Hu C; Qin L
    Discov Oncol; 2024 Aug; 15(1):333. PubMed ID: 39095628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.